The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Could BTK inhibitors still play a role in treating follicular lymphoma?
To date, BTK inhibitors have demonstrated limited efficacy as monotherapy in follicular lymphoma (FL). In this interview, Jessica Allen, MD, Huntsman Cancer Institute, Salt Lake City, UT, briefly discusses whether these agents may still play a role in FL, specifically in combination with other drug classes, such as bispecific antibodies. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
BTK inhibitors in combination with bispecifics are exciting. There was some data presented at the most recent ASH of mosunetuzumab and zanubrutinib that showed really promising response rates, so I’m excited to see that trial data mature a bit. There’s an ongoing study of that combination in relapsed follicular lymphoma as well. So I think that combination is really interesting and could show a lot of promise...
BTK inhibitors in combination with bispecifics are exciting. There was some data presented at the most recent ASH of mosunetuzumab and zanubrutinib that showed really promising response rates, so I’m excited to see that trial data mature a bit. There’s an ongoing study of that combination in relapsed follicular lymphoma as well. So I think that combination is really interesting and could show a lot of promise. BTK inhibitors alone, I would certainly reach for CAR-T and bispecifics before those in a patient that has relapsed lymphoma. Unless the patient has already progressed through those options, then maybe BTK inhibitors could still play a role where they currently are. But as of now, I’m more excited to see how they work with bispecifics in combination.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
